NBIX
NEUROCRINE BIOSCIENCES, INC.Marquee-fund ownership over time
This quarter's activity
New positions opened
Positions exited
None.
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Bridgewater Associates re-entered | Q3 2021 | 20Q | $89 | $157 | +76% |
| Renaissance Technologies | Q3 2024(8Q snapshot) | 7Q | $147 | $157 | +7% |
| Citadel Advisors | Q3 2024(8Q snapshot) | 7Q | $147 | $157 | +7% |
| Two Sigma Investments re-entered | Q3 2024(8Q snapshot) | 7Q | $147 | $157 | +7% |
| D.E. Shaw re-entered | Q3 2024(8Q snapshot) | 7Q | $147 | $157 | +7% |
| AQR Capital Management | Q3 2024(8Q snapshot) | 7Q | $147 | $157 | +7% |
| Millennium Management | Q3 2024(8Q snapshot) | 7Q | $147 | $157 | +7% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Soros Fund Management | Q3 2024 | Q3 2025 | → $131 | -10% |
| Coatue Management | Q1 2020 | Q2 2020 | → $117 | +12% |
| JANA Partners | Q4 2016 | Q2 2017 | → $53 | -3% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at NEUROCRINE BIOSCIENCES INC. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Jun 9, 2026 — the most recent Form 4 on file — not from today.
- Form 40001894425-26-000014Jun 9, 2026
- Form 40001079462-26-000006Jun 9, 2026
- Form 40001533568-26-000009Jun 8, 2026
- Form 40001776977-26-000010Jun 4, 2026
- Form 40001818524-26-000004Jun 4, 2026
- Form 40001894425-26-000012Jun 2, 2026
- Form 40001965808-26-000007Jun 2, 2026
- Form 40001894425-26-000010May 29, 2026
- Form 40001201096-26-000012May 29, 2026
- Form 40001126490-26-000005May 29, 2026
- Form 40001123343-26-000008May 29, 2026
- Form 40001782135-26-000020May 29, 2026
- Form 40001189014-26-000007May 29, 2026
- Form 40001377202-26-000006May 29, 2026
- Form 40001079462-26-000004May 29, 2026
Fundamentals
XBRL · NEUROCRINE BIOSCIENCES, INC.Annual figures sourced directly from NEUROCRINE BIOSCIENCES, INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for NEUROCRINE BIOSCIENCES INC — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KMaterial eventMay 28, 2026
- 8-KMaterial eventMay 18, 2026
- 10-QQuarterly reportMay 5, 2026
- 8-KMaterial eventMay 5, 2026
- DEF 14AProxy statementApr 15, 2026
- 8-KMaterial eventApr 6, 2026
- 10-KAnnual reportFeb 11, 2026
- 8-KMaterial eventFeb 11, 2026
- 8-KMaterial eventNov 24, 2025
- 10-QQuarterly reportOct 28, 2025
- 8-KMaterial eventOct 28, 2025
- 10-QQuarterly reportJul 30, 2025
- 8-KMaterial eventJul 30, 2025
- 8-KMaterial eventMay 30, 2025
- 8-KMaterial eventMay 22, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| D.E. Shaw | Q2 2026 | open | $158 | $157 | -1% |
| Two Sigma Investments | Q4 2025 | open | $145 | $157 | +9% |
| Citadel Advisors | Q3 2024 | open | $147 | $157 | +7% |
| Soros Fund Management | Q3 2024 | Q3 2025 | $147 | $131 | -10% |
| Two Sigma Investments | Q3 2024 | Q3 2025 | $147 | $131 | -10% |
| D.E. Shaw | Q3 2024 | Q3 2025 | $147 | $131 | -10% |
| AQR Capital Management | Q3 2024 | open | $147 | $157 | +7% |
| Millennium Management | Q3 2024 | open | $147 | $157 | +7% |
| Renaissance Technologies | Q3 2024 | open | $147 | $157 | +7% |
| Bridgewater Associates | Q2 2023 | open | $97 | $155 | +60% |
| Bridgewater Associates | Q3 2021 | Q4 2022 | $89 | $123 | +38% |
| Coatue Management | Q1 2020 | Q2 2020 | $104 | $117 | +12% |
| JANA Partners | Q4 2016 | Q2 2017 | $55 | $53 | -3% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.